We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

2 hedge funds and large institutions have $0 invested in Merrimack Pharmaceuticals, Inc. in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% less funds holding

Funds holding: 12 → 2 (-10)

100% less capital invested

Capital invested by funds: $5.32M → $0 (-$5.32M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

Holders
2
Holders Change
-10
Holders Change %
-83.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$4.83M
2
Goldman Sachs
Goldman Sachs
New York
-$451K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$37.5K
4
JC
JBF Capital
Colorado
-$1.19K
5
Marshall Wace
Marshall Wace
United Kingdom
-$1.15K
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
1
Dimensional Fund Advisors
Texas
– -$4.83M -318,995 Closed
JC
2
JBF Capital
Colorado
– -$1.19K -39,637 Closed
Marshall Wace
3
Marshall Wace
United Kingdom
– -$1.15K -38,221 Closed
Goldman Sachs
4
Goldman Sachs
New York
– -$451K -29,807 Closed
RhumbLine Advisers
5
RhumbLine Advisers
Massachusetts
– -$37.5K -2,480 Closed

MACK Hedge Fund Activity: Q3 2024 in Review

2 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2024, worth a combined $0 — down 100% from $5.32M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of MACK and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $4.83M sold.

  • 2 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2024, down from 12 in Q2 2024.
  • Funds reported $0 of Merrimack Pharmaceuticals, Inc. stock for Q3 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2024 and 10 closed out, a net change of -10 holders.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2024 was Dimensional Fund Advisors, an estimated $4.83M sold.

Based on aggregated 13F filings for Q3 2024.